Skip to main content
SpringerLink
Log in

Immune checkpoint inhibitor-based therapy: assessing the risk of pulmonary toxicity

  • Review
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Hong B, et al. Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions. Drug Safety : 7 Nov 2023. Available from: URL: https://doi.org/10.1007/s40264-023-01357-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Immune checkpoint inhibitor-based therapy: assessing the risk of pulmonary toxicity. Reactions Weekly 1983, 11 (2023). https://doi.org/10.1007/s40278-023-49360-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-49360-9

Search

Navigation